Cargando…

405例肺癌合并肺结核患者临床特征及驱动基因检测分析

BACKGROUND AND OBJECTIVE: New treatment methods such as targeted therapy and immune checkpoint inhibitors have been applied to lung cancer patients. It is necessary to further understand the patients with lung cancer combined with pulmonary tuberculosis with the development of lung cancer research....

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260389/
https://www.ncbi.nlm.nih.gov/pubmed/32336065
http://dx.doi.org/10.3779/j.issn.1009-3419.2020.101.25
_version_ 1783540301868040192
collection PubMed
description BACKGROUND AND OBJECTIVE: New treatment methods such as targeted therapy and immune checkpoint inhibitors have been applied to lung cancer patients. It is necessary to further understand the patients with lung cancer combined with pulmonary tuberculosis with the development of lung cancer research. The purpose of this study was to analyze the clinical characteristics of lung cancer patients with pulmonary tuberculosis, the status of driver genes, and their relationships. METHODS: A retrospective analysis was performed on 405 patients with lung cancer and pulmonary tuberculosis hospitalized in our hospital from January 2014 to December 2019. The relationship between clinical characteristics and driver genes status was analyzed. RESULTS: Among the 405 patients with lung cancer combined with pulmonary tuberculosis, 77.3% were male and 85.3% were patients with a history of smoking. The pathological type was mainly lung adenocarcinoma. When there were cavities in chest computed tomography (CT), squamous cell carcinoma was the main type. 214 patients underwent driver genes testing. The epidermal growth factor receptor (EGFR) gene mutation rate was 35.9%, of which 41.8% were exon 19 deletion mutations and 50.9% were exon 21 L858R mutations. When there were cavities in the chest CT, the EGFR mutation rate was significantly reduced (16.1%). The positive rate of anaplastic lymphoma kinase (ALK) fusion gene detection was 2.5%, the mutation rate of c-ros oncogene 1 receptor kinase (ROS1) gene was 1.9%, the mutation rate of V-raf murine sarcoma viral oncogene homolog B1 (BRAF) gene was 1.1%, and the mutation rate of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) gene was 10.1%. The genetic mutation rate of female patients with lung cancer and pulmonary tuberculosis was 50.0%, and that of men was 27.9%. CONCLUSION: Patients with lung cancer and pulmonary tuberculosis are predominantly male with smoking history. Adenocarcinoma is the most common pathological type. The positive rate of gene mutation was not significantly different from that of simple lung cancer, but when there were cavities in the chest image, the genetic mutation rate was significantly reduced.
format Online
Article
Text
id pubmed-7260389
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-72603892020-06-08 405例肺癌合并肺结核患者临床特征及驱动基因检测分析 Zhongguo Fei Ai Za Zhi 临床研究 BACKGROUND AND OBJECTIVE: New treatment methods such as targeted therapy and immune checkpoint inhibitors have been applied to lung cancer patients. It is necessary to further understand the patients with lung cancer combined with pulmonary tuberculosis with the development of lung cancer research. The purpose of this study was to analyze the clinical characteristics of lung cancer patients with pulmonary tuberculosis, the status of driver genes, and their relationships. METHODS: A retrospective analysis was performed on 405 patients with lung cancer and pulmonary tuberculosis hospitalized in our hospital from January 2014 to December 2019. The relationship between clinical characteristics and driver genes status was analyzed. RESULTS: Among the 405 patients with lung cancer combined with pulmonary tuberculosis, 77.3% were male and 85.3% were patients with a history of smoking. The pathological type was mainly lung adenocarcinoma. When there were cavities in chest computed tomography (CT), squamous cell carcinoma was the main type. 214 patients underwent driver genes testing. The epidermal growth factor receptor (EGFR) gene mutation rate was 35.9%, of which 41.8% were exon 19 deletion mutations and 50.9% were exon 21 L858R mutations. When there were cavities in the chest CT, the EGFR mutation rate was significantly reduced (16.1%). The positive rate of anaplastic lymphoma kinase (ALK) fusion gene detection was 2.5%, the mutation rate of c-ros oncogene 1 receptor kinase (ROS1) gene was 1.9%, the mutation rate of V-raf murine sarcoma viral oncogene homolog B1 (BRAF) gene was 1.1%, and the mutation rate of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) gene was 10.1%. The genetic mutation rate of female patients with lung cancer and pulmonary tuberculosis was 50.0%, and that of men was 27.9%. CONCLUSION: Patients with lung cancer and pulmonary tuberculosis are predominantly male with smoking history. Adenocarcinoma is the most common pathological type. The positive rate of gene mutation was not significantly different from that of simple lung cancer, but when there were cavities in the chest image, the genetic mutation rate was significantly reduced. 中国肺癌杂志编辑部 2020-05-20 /pmc/articles/PMC7260389/ /pubmed/32336065 http://dx.doi.org/10.3779/j.issn.1009-3419.2020.101.25 Text en 版权所有©《中国肺癌杂志》编辑部2020 This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/.
spellingShingle 临床研究
405例肺癌合并肺结核患者临床特征及驱动基因检测分析
title 405例肺癌合并肺结核患者临床特征及驱动基因检测分析
title_full 405例肺癌合并肺结核患者临床特征及驱动基因检测分析
title_fullStr 405例肺癌合并肺结核患者临床特征及驱动基因检测分析
title_full_unstemmed 405例肺癌合并肺结核患者临床特征及驱动基因检测分析
title_short 405例肺癌合并肺结核患者临床特征及驱动基因检测分析
title_sort 405例肺癌合并肺结核患者临床特征及驱动基因检测分析
topic 临床研究
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260389/
https://www.ncbi.nlm.nih.gov/pubmed/32336065
http://dx.doi.org/10.3779/j.issn.1009-3419.2020.101.25
work_keys_str_mv AT 405lìfèiáihébìngfèijiéhéhuànzhělínchuángtèzhēngjíqūdòngjīyīnjiǎncèfēnxī
AT 405lìfèiáihébìngfèijiéhéhuànzhělínchuángtèzhēngjíqūdòngjīyīnjiǎncèfēnxī
AT 405lìfèiáihébìngfèijiéhéhuànzhělínchuángtèzhēngjíqūdòngjīyīnjiǎncèfēnxī
AT 405lìfèiáihébìngfèijiéhéhuànzhělínchuángtèzhēngjíqūdòngjīyīnjiǎncèfēnxī
AT 405lìfèiáihébìngfèijiéhéhuànzhělínchuángtèzhēngjíqūdòngjīyīnjiǎncèfēnxī
AT 405lìfèiáihébìngfèijiéhéhuànzhělínchuángtèzhēngjíqūdòngjīyīnjiǎncèfēnxī